References
- Hayes DF, Allen J, Compton C, et al. Tumor biomarker diagnostics. breaking a vicious cycle. Sci Transl Med 2013;5:196cm196
- Frueh FW. Regulation, reimbursement, and the long road of implementation of personalized medicine – a perspective from the United States. Value Health 2013;16(6 Suppl):S27-31
- Trusheim MR, Austin MJ, Rausch C, Berndt ER. Uncertain prognosis for high-quality diagnostics: clinical challenges, economic barriers and needed reforms. Pharmacogenomics 2013;14(3):325-34
- Davis JC, Furstenthal L, Desai AA, et al. The microeconomics of personalized medicine: today’s challenge and tomorrow’s promise. Nat Rev Drug Discov 2009;8(4):279-86
- Hutton J, McGrath C, Frybourgh JM, et al. Framework for describing and classifying decision-making systems using technology assessment to determine the reimbursement of health technologies (fourth hurdle systems). Intern J Technol Assess 2006;22:10-18
- Hamburg MA, Collins FS. The path to personalized medicine. N Engl J Med 2010;363(4):301-4
- FDA. Paving the way for personalized medicine. 2013. Available from: www.fda.gov/downloads/scienceresearch/specialtopics/personalizedmedicine/ucm372421.pdf
- FDA. Personalized Medicine. 2014. Available from: www.fda.gov/ScienceResearch/SpecialTopics/PersonalizedMedicine/default.htm
- FDA. Genomics guidances and concept papers. 2014. Available from: www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083374.htm
- FDA. Biomarker Qualification Program. 2014. Available from: www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugDevelopmentToolsQualificationProgram/ucm284076.htm
- FDA. In vitro companion diagnostic devices [draft guidance]. 2011. Available from: www.fda.gov/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm262292.htm
- FDA. Drug-diagnostic co-development concept paper. 2005. Available from: www.fda.gov/downloads/drugs/scienceresearch/researchareas/pharmacogenetics/ucm116689.pdf
- European Medicines Agency. Pharmacogenomics and personalized medicine. 2014. Available from: www.ema.europa.eu/ema/index.jsp?curl=pages/special_topics/general/general_content_000347.jsp&mid=WC0b01ac05800baeda
- Agency for Healthcare Research & Quality [U.S.]. Methods guide for medical test reviews, p. 8, Fig. I-1. 2010. Available from: www.effectivehealthcare.ahrq.gov/tasks/sites/ehc/assets/File/methods_guide_for_medical_tests.pdf
- Evans AS. Causation and disease: a chronological journey. The Thomas Parran Lecture. Am J Epidemiol 1978;108:249-58
- Fryback DG, Thornbury JR. The efficacy of diagnostic imaging. Med Decis Making 1991;11:88-94
- Tajik P, Zwinderman AH, Mol BW. Trial designs for personalized cancer care: a systematic review and classification. Clin Cancer Res 2013;19:4578-88
- WHO. Quality & safety in genetic testing: an emerging concern. Available from: www.who.int/genomics/policy/quality_safety/en/index1.html
- Simon RM, Paik S, Hayes DM. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 2009;101:1446-52
- Goozner M. Duke scandal highlights need for genomics research criteria. J Natl Cancer Inst 2011;103:916-17
- Gilstrap LG, Wang TJ. Biomarkers and cardiovascular risk assessment for primary prevention: an update. Clin Chem 2012;58:72-82
- Health Technology Assessment (11, No. 50): evaluation of diagnostic tests when there is no gold standard. A review of methods. Available from: www.journalslibrary.nihr.ac.uk/__data/assets/pdf_file/0020/64730/FullReport-hta11500.pdf
- Centers for Medicare & Medicaid, MEDCAC Advisory Committee. Presentation materials, technology assessment, and transcript. 2013. Available from: www.cms.gov/medicare-coverage-database/details/medcac-meeting-details.aspx?MEDCACId=67
- Parkinson DR, McCormack RT, Keating SM, et al. Evidence of clinical utility: an unmet need in molecular diagnostics for patients with cancer. Clin Cancer Res 2014;20(6):1428-44
- Yang L, Rieves D, Ganley C. Brain amyloid imaging - FDA approval of florbetapir F18 injection. N Engl J Med 2012;367:885-7
- McGaughan M. The value of knowing: CMS rejects coverage for Lilly’s Amyvid - except as a tool for further research. RPM Rep 2013;24:2013
- Staub LP, Lord SJ, Simes JR, et al. Using patient management as a surrogate for patient health outcomes in diagnostic test evaluation. BMC Med Res Methodol 2012;12:12
- Dubois RW, Lauer M, Perfetto E. When is evidence sufficient for decision-making? A framework for understanding the pace of evidence adoption. J Comp Eff Res 2013;2:383-91
- Ferrante di Ruffano L, Hyde CJ, McCaffery KJ, et al. Assessing the value of diagnostic tests: a framework for designing and evaluating trials. BMJ 2012;344:e686
- American Society of Clinical Oncology, Leadership Summit to address value in cancer care, cost of cancer drugs and technologies. 2014. Available from: www.asco.org/advocacy/asco-holds-leadership-summit-address-value-cancer-care-cost-cancer-drugs-and-technologies
- Centers for Medicare & Medicaid, Decision Memo for Beta Amyloid Positron Emission Tomography in Dementia (CAG 00431-N). 2013. Available from: www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=265References